Tumor Etiology and Screening Department of Cancer Institute and General Surgery, Liaoning Provincial Education Department, The First Affiliated Hospital of China Medical University, and Key Laboratory of Cancer Etiology and Prevention (China Medical University), Shenyang, China.
Department of Biochemistry & Molecular Biology, China Medical University, Shenyang, China.
Cancer Med. 2018 Aug;7(8):4068-4076. doi: 10.1002/cam4.1615. Epub 2018 Jul 2.
Gastric tumorigenesis is a multistep process initiated by chronic superficial gastritis (SG), followed by atrophic gastritis (AG), then intestinal metaplasia (IM), and finally by dysplasia and adenocarcinoma according to the Correa model. Pepsinogen C (PGC) decreases gradually during progression of cancer, which makes PGC an ideal negative marker for GC. To explore the correlation between PGC and other positive tumor markers in different gastric diseases, we observed the expression of PGC, MG7-Ag, MMP9, NM23, Ki-67, and E-cadherin by immunohistochemistry, quantitative RT-PCR, and immunoblot analysis. Our results showed that in SG, PGC was highly expressed while malignant phenotype markers were rarely expressed. In contrast with SG, malignant phenotype markers were highly expressed while the positive rate of PGC reached only 1.44% in GC. So there was no coexpression of PGC and malignant phenotype markers in SG or GC tissues. Only in the AG group, which is well-known to be gastric precancerous disease, coexpression of PGC and malignant phenotype markers was detected. Our results suggested that the expression of PGC in AG was negatively correlated with that of MG7-Ag and MMP9. Of all AG, those with low expression of PGC and high expression of MG7-Ag and MMP9 may possess a greater potential of malignant transformation. Combined detection of negative marker PGC and positive markers MG7-Ag and MMP9 could be used as a potential follow-up panel for monitoring dynamical progression of AG and improving the detection efficiency of high-risk individuals of gastric cancer, and then taking necessary interventions on the target population.
胃癌的发生是一个多步骤的过程,始于慢性浅表性胃炎(SG),随后是萎缩性胃炎(AG),接着是肠上皮化生(IM),最后根据 Correa 模型发展为异型增生和腺癌。在癌症进展过程中,胃蛋白酶原 C(PGC)逐渐减少,这使得 PGC 成为 GC 的理想阴性标志物。为了探讨 PGC 与不同胃部疾病中其他阳性肿瘤标志物的相关性,我们通过免疫组织化学、定量 RT-PCR 和免疫印迹分析观察了 PGC、MG7-Ag、MMP9、NM23、Ki-67 和 E-cadherin 的表达。我们的结果表明,在 SG 中,PGC 高度表达,而恶性表型标志物很少表达。与 SG 相反,恶性表型标志物高度表达,而 GC 中的 PGC 阳性率仅为 1.44%。因此,在 SG 或 GC 组织中,PGC 与恶性表型标志物没有共表达。仅在众所周知的胃癌前病变 AG 组中检测到 PGC 和恶性表型标志物的共表达。我们的结果表明,AG 中 PGC 的表达与 MG7-Ag 和 MMP9 的表达呈负相关。在所有的 AG 中,那些 PGC 低表达、MG7-Ag 和 MMP9 高表达的患者可能具有更大的恶性转化潜力。联合检测阴性标志物 PGC 和阳性标志物 MG7-Ag 和 MMP9 可作为监测 AG 动态进展和提高胃癌高危人群检测效率的潜在随访指标,并对目标人群进行必要的干预。